These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68 related articles for article (PubMed ID: 10442639)
1. Inhibition of MT-450 rat mammary tumour growth by antibodies recognising subtypes of blood group antigen B. Sleeman JP; Kim U; LePendu J; Howells N; Coquerelle T; Ponta H; Herrlich P Oncogene; 1999 Aug; 18(31):4485-94. PubMed ID: 10442639 [TBL] [Abstract][Full Text] [Related]
2. Immunoglobulin G3 monoclonal antibody directed to Tn antigen (tumor-associated alpha-N-acetylgalactosaminyl epitope) that does not cross-react with blood group A antigen. Takahashi HK; Metoki R; Hakomori S Cancer Res; 1988 Aug; 48(15):4361-7. PubMed ID: 3390832 [TBL] [Abstract][Full Text] [Related]
3. Involvement of H type 1 carbohydrate antigen in cell adhesion to vascular endothelial cells of human endometrial cancer. Sakuma Y; Kubushiro K; Tsukazaki K; Nozawa S Anticancer Res; 2003; 23(2B):1277-82. PubMed ID: 12820383 [TBL] [Abstract][Full Text] [Related]
4. A tumor-associated organ-specific antigen characteristic of spontaneously metastatic rat mammary carcinomas. Ghosh SK; Grossberg AL; Kim U; Pressman D J Natl Cancer Inst; 1979 May; 62(5):1229-33. PubMed ID: 286100 [TBL] [Abstract][Full Text] [Related]
5. Xenotransplantation and ABO incompatible transplantation: the similarities they share. Galili U Transfus Apher Sci; 2006 Aug; 35(1):45-58. PubMed ID: 16905361 [TBL] [Abstract][Full Text] [Related]
6. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Rabbani SA; Gladu J Cancer Res; 2002 Apr; 62(8):2390-7. PubMed ID: 11956102 [TBL] [Abstract][Full Text] [Related]
7. Case report: diffuse splenic metastasis of occult breast cancer with incompatible blood group antigenic determinants. Baranyay F Acta Histochem; 2009; 111(4):343-8. PubMed ID: 19201455 [TBL] [Abstract][Full Text] [Related]
8. Loss of myoepithelial cell characteristics in metastasizing rat mammary tumors relative to their nonmetastasizing counterparts. Dunnington DJ; Kim U; Hughes CM; Monaghan P; Ormerod EJ; Rudland PS J Natl Cancer Inst; 1984 Feb; 72(2):455-66. PubMed ID: 6198552 [TBL] [Abstract][Full Text] [Related]
9. A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype. Boukerche H; Baril P; Tabone E; Bérard F; Sanhadji K; Balme B; Wolf F; Perrot H; Thomas L Cancer Res; 2000 Oct; 60(20):5848-56. PubMed ID: 11059782 [TBL] [Abstract][Full Text] [Related]
10. Toremifene resistance in a rat mammary tumour model. Kellen JA; Georges E; Ling V; Dubsky M Anticancer Res; 1992; 12(5):1663-5. PubMed ID: 1359832 [TBL] [Abstract][Full Text] [Related]
11. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors. Scott AM; Geleick D; Rubira M; Clarke K; Nice EC; Smyth FE; Stockert E; Richards EC; Carr FJ; Harris WJ; Armour KL; Rood J; Kypridis A; Kronina V; Murphy R; Lee FT; Liu Z; Kitamura K; Ritter G; Laughton K; Hoffman E; Burgess AW; Old LJ Cancer Res; 2000 Jun; 60(12):3254-61. PubMed ID: 10866319 [TBL] [Abstract][Full Text] [Related]
12. Growth hormone in vascular pathology: neovascularization and expression of receptors is associated with cellular proliferation. Lincoln DT; Singal PK; Al-Banaw A Anticancer Res; 2007; 27(6B):4201-18. PubMed ID: 18225592 [TBL] [Abstract][Full Text] [Related]
13. Neutralization of blood group A-antigen by a novel anti-A antibody: overcoming ABO-incompatible solid-organ transplantation. Hasegawa Y; Kato Y; Kaneko MK; Ogasawara S; Shimazu M; Tanabe M; Kawachi S; Obara H; Shinoda M; Kitagawa Y; Narimatsu H; Kitajima M Transplantation; 2008 Feb; 85(3):378-85. PubMed ID: 18322429 [TBL] [Abstract][Full Text] [Related]
15. ABO-incompatible live donor renal transplantation using blood group A/B carbohydrate antigen immunoadsorption and anti-CD20 antibody treatment. Nordén G; Briggs D; Cockwell P; Lipkin G; Mjörnstedt L; Mölne J; Ready A; Rydberg L; Samuelsson O; Svalander CT; Breimer ME Xenotransplantation; 2006 Mar; 13(2):148-53. PubMed ID: 16623810 [TBL] [Abstract][Full Text] [Related]
16. Rat umbilical cord stem cells completely abolish rat mammary carcinomas with no evidence of metastasis or recurrence 100 days post-tumor cell inoculation. Ganta C; Chiyo D; Ayuzawa R; Rachakatla R; Pyle M; Andrews G; Weiss M; Tamura M; Troyer D Cancer Res; 2009 Mar; 69(5):1815-20. PubMed ID: 19244122 [TBL] [Abstract][Full Text] [Related]
17. Hormone-responsive growth in vivo of a tissue culture cell line established from the MT-W9A rat mammary tumor. Sirbasku DA Cancer Res; 1978 Apr; 38(4):1154-65. PubMed ID: 639042 [No Abstract] [Full Text] [Related]
18. Interleukin-24 induces expression of beta4 integrin but suppresses anchorage-independent growth of rat mammary tumor cells by a mechanism that is independent of beta4. Xuan W; Li YJ; Liu G; Ben-David Y; Archer MC Mol Cancer Res; 2009 Mar; 7(3):433-42. PubMed ID: 19258414 [TBL] [Abstract][Full Text] [Related]
19. Eukaryotic expression cloning with an antimetastatic monoclonal antibody identifies a tetraspanin (PETA-3/CD151) as an effector of human tumor cell migration and metastasis. Testa JE; Brooks PC; Lin JM; Quigley JP Cancer Res; 1999 Aug; 59(15):3812-20. PubMed ID: 10447000 [TBL] [Abstract][Full Text] [Related]
20. Metastasis control by injection of blood lymphocytes cultured with neuraminidase-treated MT/W 449A rat mammary carcinoma. Watkins E; Anderson LL; Baralt OL; Heatley GJ J Biol Response Mod; 1984; 3(1):60-75. PubMed ID: 6707700 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]